2. Academic Validation
  3. Loss of PRDM11 promotes MYC-driven lymphomagenesis

Loss of PRDM11 promotes MYC-driven lymphomagenesis

  • Blood. 2015 Feb 19;125(8):1272-81. doi: 10.1182/blood-2014-03-560805.
Cathrine Kolster Fog 1,  Fazila Asmar 2,  Christophe Côme 1,  Klaus Thorleif Jensen 1,  Jens Vilstrup Johansen 1,  Tony Bou Kheir 1,  Linda Jacobsen 1,  Carsten Friis 1,  Alison Louw 1,  Louise Rosgaard 1,  Nina Friesgaard Øbro 3,  Hanne Vibeke Marquart 3,  Kristian Anthonsen 4,  Arie Koen Braat 5,  Maarten van Lohuizen 5,  Elisabeth Ralfkiaer 6,  Kirsten Grønbæk 7,  Anders Henrik Lund 1
Affiliations

Affiliations

  • 1 Biotech Research and Innovation Centre and Centre for Epigenetics, University of Copenhagen, Copenhagen, Denmark;
  • 2 Department of Hematology.
  • 3 Department of Clinical Immunology, and.
  • 4 Department of Otorhinolaryngology, Head and Neck Surgery and Audiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark;
  • 5 Division of Molecular Genetics, Netherlands Cancer Institute, Amsterdam, The Netherlands; and.
  • 6 Department of Pathology, Rigshospitalet, Copenhagen, Denmark.
  • 7 Biotech Research and Innovation Centre and Centre for Epigenetics, University of Copenhagen, Copenhagen, Denmark; Department of Hematology.
PMID: 25499759 DOI: 10.1182/blood-2014-03-560805
Abstract

The PR-domain (PRDM) family of genes encodes transcriptional regulators, several of which are deregulated in Cancer. By using a functional screening approach, we sought to identify novel tumor suppressors among the PRDMs. Here we demonstrate oncogenic collaboration between depletion of the previously uncharacterized PR-domain family member Prdm11 and overexpression of MYC. Overexpression of PRDM11 inhibits proliferation and induces Apoptosis. Prdm11 knockout mice are viable, and loss of Prdm11 accelerates MYC-driven lymphomagenesis in the Eµ-Myc mouse model. Moreover, we show that patients with PRDM11-deficient diffuse large B-cell lymphomas (DLBCLs) have poorer overall survival and belong to the nongerminal center B-cell-like subtype. Mechanistically, genome-wide mapping of PRDM11 binding sites coupled with transcriptome Sequencing in human DLBCL cells evidenced that PRDM11 associates with transcriptional start sites of target genes and regulates important oncogenes such as FOS and JUN. Hence, we characterize PRDM11 as a putative novel tumor suppressor that controls the expression of key oncogenes, and we add new mechanistic insight into B-cell lymphomagenesis.

Figures